Mutations in SCN3A Cause Early Infantile Epileptic Encephalopathy

Tariq Zaman, PhD,1 Ingo Helbig, MD,1,2,3 Ivana Babić Božović, MD, PhD,4 Suzanne D. DeBrosse, MD,5 A. Christina Bergqvist, MD,1 Kimberly Wallis, LCGC,5 Livija Medne, MS, LCGC,6 Aleš Maver, MD, PhD,7 Borut Peterlin, PhD,7 Katherine L. Helbig, MS, LCGC 1,1,8 Xiaohong Zhang, PhD,1 and Ethan M. Goldberg, MD, PhD 1,3,9

Objective: Voltage-gated sodium (Na+) channels underlie action potential generation and propagation and hence are central to the regulation of excitability in the nervous system. Mutations in the genes SCN1A, SCN2A, and SCN8A, encoding the Na+ channel pore-forming (α) subunits Nav1.1, 1.2, and 1.6, respectively, and SCN1B, encoding the accessory subunit β1, are established causes of genetic epilepsies. SCN3A, encoding Nav1.3, is known to be highly expressed in brain, but has not previously been linked to early infantile epileptic encephalopathy. Here, we describe a cohort of 4 patients with epileptic encephalopathy and heterozygous de novo missense variants in SCN3A (p.Ile875Thr in 2 cases, p.Pro1333Leu, and p.Val1769Ala).

Methods: All patients presented with treatment-resistant epilepsy in the first year of life, severe to profound intellectual disability, and in 2 cases (both with the variant p.Ile875Thr), diffuse polymicrogyria.

Results: Electrophysiological recordings of mutant channels revealed prominent gain of channel function, with a markedly increased amplitude of the slowly inactivating current component, and for 2 of 3 mutants (p.Ile875Thr and p.Pro1333Leu), a leftward shift in the voltage dependence of activation to more hyperpolarized potentials. Gain of function was not observed for Nav1.3 variants known or presumed to be inherited (p.Arg1642Cys and p.Lys1799Gln). The antiseizure medications phenytoin and lacosamide selectively blocked slowly inactivating over transient current in wild-type and mutant Nav1.3 channels.

Interpretation: These findings establish SCN3A as a new gene for infantile epileptic encephalopathy and suggest a potential pharmacologic intervention. These findings also reinforce the role of Nav1.3 as an important regulator of neuronal excitability in the developing brain, while providing additional insight into mechanisms of slow inactivation of Nav1.3.

View this article online at wileyonlinelibrary.com. DOI: 10.1002/ana.25188

Received Nov 17, 2017, and in revised form Feb 1, 2018. Accepted for publication Feb 18, 2018.

Address correspondence to Dr Goldberg, Children's Hospital of Philadelphia, Abramson Research Center, Room 502A, Philadelphia, PA 19104. E-mail: goldberge@email.chop.edu

From the 1Division of Neurology, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, PA; 2Department of Neuropediatrics, University Medical Center Schleswig-Holstein, Christian Albrecht University, Kiel, Germany; 3Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; 4Department of Biology and Medical Genetics, School of Medicine, University of Rijeka, Rijeka, Croatia; 5Departments of Genetics and Genome Sciences, Pediatrics, and Neurology, and Center for Human Genetics, Case Western Reserve University School of Medicine, Cleveland, OH; 6Division of Human Genetics, Department of Pediatrics, Individualized Medical Genetics Center, Children's Hospital of Philadelphia, Philadelphia, PA; 7Clinical Institute of Medical Genetics, University Medical Centre Ljubljana, Ljubljana, Slovenia; 8Division of Clinical Genomics, Ambry Genetics, Aliso Viejo, CA; and 9Department of Neuroscience, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

© 2018 American Neurological Association
The predominant Na\(^+\) channels expressed in brain are Nav1.1, 1.2, 1.3, and 1.6.\(^1\) Mutations in the genes encoding 3 of these 4 channels are highly associated with epilepsy; heterozygous loss of function mutation of SCN1A (encoding Nav1.1) is the major cause of Dravet syndrome spectrum disorders.\(^5,6\) Mutations of SCN2A\(^7–9\) (encoding Nav1.2) and SCN8A\(^10,11\) (encoding Nav1.6) are also well-established causes of genetic epilepsy, associated with a wider phenotypic spectrum that includes early infantile epileptic encephalopathy. However, a link between Nav1.3 and epilepsy has been less clear. SCN3A encodes the type 3 voltage-gated Na\(^+\) channel \(\alpha\) subunit Nav1.3, which is known to be highly expressed in embryonic brain.\(^12,13\) Postnatal expression levels in rodents is low or undetectable,\(^14,15\) although Nav1.3 is upregulated in response to various insults to the nervous system including nerve injury\(^16,17\) and in some rodent models of epilepsy.\(^18,19\) However, Nav1.3 knockout mice appear healthy.\(^16\) A specific function of Nav1.3 in brain is not clear. However, it has been consistently noted that Nav1.3 current includes a relatively prominent slowly inactivating/“persistent” current component \((I_{NaP})\) of between 0.5 and 10.3% of peak transient sodium current \((I_{NaT})\).\(^20–22\)

Previous studies have reported heterozygous variants in SCN3A in association with less severe forms of epilepsy;\(^21–25\) however, de novo mutation in SCN3A as a cause of early infantile epileptic encephalopathy has yet to be described. Prior reports include cases of focal epilepsy, with onset after infancy, and not consistently associated with developmental delay/intellectual disability; variants were in most instances not shown definitively to be de novo mutations. Here, we describe a cohort of 4 patients with infantile onset epileptic encephalopathy due to verified de novo mutation of SCN3A, and characterize the functional consequences of these mutations electrophysiologically. We also assess the electrophysiological properties of 2 SCN3A variants that were either demonstrated or suspected to be inherited. These latter variants did not show the gain of function seen in patients with a proven de novo mutation and early infantile epileptic encephalopathy. Our results support the status of SCN3A as an early infantile epileptic encephalopathy gene and further suggest that the mechanism of severe epilepsy is gain of function; our results show a prominent increase in \(I_{NaP}\) and, for 2 of the 3 mutants, an apparent leftward shift in the voltage dependence of channel activation.

### Subjects and Methods

#### Study Subjects

Patients included in the study (Table 1) were either seen and evaluated at the Children's Hospital of Philadelphia (Philadelphia, PA), the University Hospitals Cleveland Medical Center (Cleveland, OH), or the Clinical Institute of Medical Genetics, University Medical Centre Ljubljana (Ljubljana, Slovenia), or were ascertained through a collaboration with Ambry Genetics (Aliso Viejo, CA). Informed consent was obtained from all parent(s) where applicable. This study was approved by the local institutional review boards at each of the participating institutions.

### Table 1. Epilepsy-Associated Nav1.3 Mutant Channels: Present Report

<table>
<thead>
<tr>
<th>Patient</th>
<th>Amino Acid Change</th>
<th>Domain Segment</th>
<th>Inheritance Pattern</th>
<th>Epilepsy Age of Onset</th>
<th>EEG Classification</th>
<th>Seizure Semiology</th>
<th>DD</th>
<th>MRI</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>p.I875T</td>
<td>2</td>
<td>4–5 linker</td>
<td>De novo</td>
<td>2 wk</td>
<td>Multifocal</td>
<td>Profound PMG</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>p.I875T</td>
<td>2</td>
<td>4–5 linker</td>
<td>De novo</td>
<td>2 wk</td>
<td>Multifocal</td>
<td>Profound PMG</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>p.P1333L</td>
<td>3</td>
<td>4–5 linker</td>
<td>De novo</td>
<td>1–3 days</td>
<td>Hypsarrhythmia; multifocal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>p.V1769A</td>
<td>4</td>
<td>6</td>
<td>De novo</td>
<td>&lt;1 yr</td>
<td>Multifocal</td>
<td>NA</td>
<td>Yes</td>
</tr>
<tr>
<td>5</td>
<td>p.R1642C</td>
<td>4</td>
<td>5</td>
<td>Unknown*</td>
<td>18 mo</td>
<td>NA</td>
<td>Focal onset with impaired awareness</td>
<td>Normal</td>
</tr>
</tbody>
</table>

*Nonmaternal; father not available for testing.
DD = developmental delay; EEG = electroencephalographic; MRI = magnetic resonance imaging; NA = not available for review; PMG = polymicrogyria.
Patient 1 was a male with epilepsy onset at age 2 weeks, with continued intractable epilepsy at last follow-up (at age 13 years), accompanied by microcephaly, profound global developmental delay, and central hypotonia. There were multiple seizure types including tonic and myoclonic seizures. At last follow-up, the patient remained nonverbal and nonambulatory, with dysphagia and failure to thrive requiring exclusive feeding via gastrostomy tube. Magnetic resonance imaging (MRI) of the brain showed extensive frontoparietal polymicrogyria with thickening of the cerebral cortex. Trio whole exome sequencing (WES) analysis revealed a de novo heterozygous c.5306T>C missense mutation in SCN3A leading to a p.Val1769Ala amino acid substitution. MRI demonstrated a de novo c.5306T>C missense mutation leading to a p.Val1769Ala amino acid substitution. WES revealed a de novo heterozygous c.5306T>C missense mutation in SCN3A leading to an p.Ile875Thr amino acid substitution (based on National Center for Biotechnology Information Reference Sequence NP_008853.3 for human Nav1.3 isoform 1; see below).

Patient 2 was a female born at term after an uncomplicated pregnancy and delivery, with onset of seizures at age 2 weeks that were described as generalized tonic. MRI of the brain showed diffuse, bilateral polymicrogyria, abnormal white matter, and thin corpus callosum. The patient was also found to have a de novo c.2624T>C missense mutation leading to a p.Ile875Thr amino acid substitution. As of last follow-up, at age 3 years, the patient exhibited severe global developmental delay, central hypotonia, spastic tetraparesis, and intractable epilepsy.

Patient 3, a male born at full term, had onset of seizures on day of life 1 (36 hours), characterized by bradycardia, oxygen desaturation, and tonic unilateral upper extremity movements. An initial electroencephalogram (EEG) performed at age 2 weeks showed hypersynchronia, with high-amplitude multifocal epileptiform discharges along with eye deviation or tonic unilateral limb movements associated with electrodecrement; classical flexor or extensor spasms were not noted. Repeat EEG at age 6 months showed multifocal sharp waves and spikes and multifocal areas of intermittent slowing. Epilepsy remained refractory to treatment at last follow-up at approximately 2 years of age, at which time the patient exhibited severe global developmental delay, central hypotonia, and cortical blindness. Seizure types included unilateral clonic or tonic–clonic movements of an extremity, ipsilateral facial twitching, and/or upward or lateral eye deviation. MRI of the brain showed thinning of the corpus callosum and low–normal myelination of the cerebral white matter; head circumference was normal. WES revealed a de novo heterozygous c.3998C>T missense mutation in SCN3A leading to a p.Pro1333Leu amino acid substitution.

Patient 4, a female, had epilepsy onset within the first year of life, although exact age of onset is unknown. There was continued developmental delay and intractable epilepsy at age 4 years. EEG showed multifocal epileptiform discharges. WES demonstrated a de novo c.5306T>C missense mutation in SCN3A leading to a Val1769Ala amino acid substitution. MRI of the brain was not performed.

Patient 5, a male, had normal early childhood development, with epilepsy onset at 18 months. Epilepsy became intractable by age 3 years, with developmental arrest and regression of speech/language and motor development. At last follow-up at age 32 years, the patient continued to suffer from intractable epilepsy with minimal independent ambulation and severe intellectual impairment. Seizures have been of apparent focal onset, with arrest of activity and staring, sometimes progressing to limb stiffening and occasional falling. MRI of the brain was normal, showing only a likely posterior fossa arachnoid cyst. Neurological examination was significant for low axial tone and peripheral spasticity. WES revealed a c.4924C>T missense variant leading to a p.Arg1642Cys substitution in SCN3A that was shown to be not inherited from the patient’s mother; however, the inheritance pattern could not be strictly established, as the patient’s biological father was not available for testing.

Patient 6 had onset of infantile spasms at age 4 months accompanied by developmental arrest. By age 17 years, the patient exhibited severe intellectual impairment and was nonverbal, with ataxic gait, continued seizures, and a hyperkinetic movement disorder. WES analysis revealed a c.5395A>C variant in SCN3A leading to a p.Lys1799Gln amino acid substitution in Nav1.3 that was subsequently shown to be maternally inherited and was hence considered a variant of uncertain significance.

Exome analysis in all cases included more detailed evaluation of variants in genes associated with developmental delay, epilepsy, and brain malformation. All variants in SCN3A were confirmed via Sanger sequencing.

Cell Culture, Plasmid Preparation, and Transfection

Transfections and electrophysiological experiments were performed using tsA-201 cells. Cells were grown at 37°C with 5% CO2 in Dulbecco modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum, 2mM L-glutamine, and penicillin (50 U/mL)–streptomycin (50 µg/mL).

A plasmid encoding the major splice isoform of human SCN3A (isoform 2, which is 49 amino acids longer than isoform 1) was used (Reference Sequence NP_001075145.1), and variants were introduced by site-directed mutagenesis. Constructs were propagated in STBL2 cells at 30°C (Invitrogen, Carlsbad, CA). All plasmid preparations were resequenced prior to transfection. Plasmids encoding human sodium channel auxiliary subunits β1 (hβ1-V5-2A-dsRed) or β2 (pGFP-IRES-hβ2) were cotransfected in vectors containing marker genes facilitating the identification of cells expressing all 3 constructs (Nav1.3, Navβ1, and Navβ2). We performed transient transfection of 2 µg total cDNA at a ratio of Nav1.3, β1, and β2 of 10:1:1 using Lipofectamine 2000 (Invitrogen) transfection reagent. Cells were incubated for 48 hours after transfection prior to electrophysiological recording. Transfected cells were dissociated by brief exposure to trypsin/ethylenediaminetetraacetic acid, resuspended in supplemented DMEM medium, plated on 15mm glass coverslips, and allowed to recover for at least 4 hours at 37°C in 5% CO2 prior to recording.
**Electrophysiology**

Glass coverslips were placed in a chamber housed on the stage of an upright epifluorescence microscope for electrophysiological recording. Extracellular solution contained, in mM: NaCl, 145; KCl, 4.0; CaCl$_2$, 1.8; MgCl$_2$, 1.8; hydroxyethylpiperazine ethane sulfonic acid (HEPES), 10. pH was adjusted to 7.35 with NaOH. Intracellular pipette-filling solution contained, in mM: CsF, 110; NaCl, 10; CsCl, 20; ethyleneglycoltetraacetic acid, 2.0; HEPES, 10. pH was adjusted to 7.35 with CsOH and osmolarity to 305mOsm/l with sucrose. All chemicals were produced by Sigma-Aldrich (St Louis, MO). Recordings were performed using an agar bridge (2% in extracellular solution) produced by Sigma-Aldrich (St Louis, MO). Peak current and total charge (area under the curve; in Coulombs) were calculated.

Pharmacologic experiments were performed via bath perfusion. 5,5-Diphenyldihydantoin (phenytoin) was from Sigma-Aldrich. Lacosamide (L098500) was purchased from Toronto Research Chemicals (Toronto, Ontario, Canada), dissolved in methanol, and stored as 100mM stock solution prior to 1:1,000 dilution in extracellular solution. For such experiments, control extracellular solution contained the same final concentration of methanol (0.0998%).

All recordings and data analysis were performed blind to experimental group.

**Data Analysis**

Data for standard electrophysiological parameters were obtained from at least n = 12 cells (1 from each coverslip) from at least 6 separate transfections for each experiment. Data were analyzed using Clampfit 10.6 (Molecular Devices) or using custom scripts written in MATLAB (MathWorks, Natick, MA), and statistics were generated and plotted using Statistical Package for the Social Sciences version 14 (SPSS, Chicago, IL), Microsoft Excel (Microsoft, Redmond, WA), Prism (GraphPad Software, La Jolla, CA), and Sigma Plot 11 (Systat Software, San Jose, CA). Results are presented as the mean ± standard error of the mean, and statistical significance was established using the p value calculated from a paired or unpaired Student t test, or via 1-way analysis of variance (ANOVA) with Bonferroni correction for multiple comparisons, as appropriate, with the p value specified at the p < 0.05, 0.01, or 0.001 level, or reported exactly.

**Results**

We identified a cohort of 4 patients with severe infantile onset epileptic encephalopathy and de novo heterozygous variants in SCN3A encoding the type 3 voltage-gated Na$^+$ channel α subunit Nav1.3 (Fig 1, Table 1). Two of the patients (Patients 1 and 2) carried the same de novo p.Ile875Thr variant, whereas the other 2 patients harbored unique de novo variants p.Pro1333Leu and p.Val1769Ala. We also included 2 patients with SCN3A variants that were presumed (Patient 5) or demonstrated to be inherited (Patient 6). The 4 patients (Patients 1–4) with confirmed de novo mutation had intractable epilepsy with onset during infancy and severe to profound developmental delay. MRI of the brain was essentially normal in all cases except for the 2 patients with

\[ V_{1/2} \] of inactivation and slope factor \( k \). Kinetics of recovery from channel inactivation was determined using a 1-second prepulse to −10mV from a holding potential of −120mV followed by a variable time delay to a 10-millisecond test pulse to −10mV. Data were fit with a double exponential function to determine the first (\( \tau_1 \)) and second (\( \tau_2 \)) time constants of recovery and their relative weights.

Ramp currents were obtained using a voltage ramp from −120 to +40mV at 0.8mV/ms. Peak current and total charge (area under the curve; in Coulombs) were calculated.

**Electrophysiology**

Glass coverslips were placed in a chamber housed on the stage of an upright epifluorescence microscope for electrophysiological recording. Extracellular solution contained, in mM: NaCl, 145; KCl, 4.0; CaCl$_2$, 1.8; MgCl$_2$, 1.8; hydroxyethylpiperazine ethane sulfonic acid (HEPES), 10. pH was adjusted to 7.35 with NaOH. Intracellular pipette-filling solution contained, in mM: CsF, 110; NaCl, 10; CsCl, 20; ethyleneglycoltetraacetic acid, 2.0; HEPES, 10. pH was adjusted to 7.35 with CsOH and osmolarity to 305mOsm/l with sucrose. All chemicals were produced by Sigma-Aldrich (St Louis, MO). Recordings were performed using an agar bridge (2% in extracellular solution) reference electrode.

Recording pipettes were fashioned from thin-walled borosilicate glass (Sutter Instruments, Novato, CA) using a 2-stage upright puller (PC-10; Narishige, Tokyo, Japan), fire-polished using a microforge (MF-830, Narishige), and coated with Sylgard 182 (Dow Corning, Midland, MI). The resistance of pipettes when placed in extracellular solution was 2.18 ± 0.04MΩ. Cells that were positive for both red fluorescent protein (β₁ expression) and green fluorescent protein (β₂ expression) and exhibited fast transient inward current consistent with a voltage-gated sodium current were selected for subsequent analysis.

Whole cell patch clamp recordings were performed at room temperature (22–24°C) using a MultiClamp 700B amplifier (Molecular Devices, Sunnyvale, CA). Pipette capacitance was zeroed after formation of a gigascale. Access resistance was 4.75 ± 0.16MΩ, and recording was initiated after 10 minutes of equilibration, after which recorded currents were found to be stable, and voltage errors were reduced via partial series resistance compensation. Voltage clamp pulses were generated using Clampex 10.6, acquired at 10kHz, and filtered at 5kHz. Leak was subtracted either using a standard P/4 protocol or post hoc using a similar method involving a small prepulse. Cells were rejected from analysis if access resistance changed >15% during the recording.

The activation protocol was performed using 20-millisecond steps from a holding potential of −120mV to potentials ranging from −80mV to a maximum of 50mV, in 5mV increments, with a 10-second intersweep interval. Current was converted to current density (pA/pF) by normalizing to cell capacitance. Conductance was derived using $G = I / (V - E_{ES})$, where $G$ is conductance, $I$ is current, $V$ is voltage, and $E_{ES}$ is the calculated equilibrium potential for sodium (+68.0mV). Conductance was normalized to maximum conductance, which was fit with a Boltzmann function to determine the voltage at half-maximal channel activation ($V_{1/2}$ of activation) and slope factor $k$. Persistent current was measured as the average value of the current response in the last 10 milliseconds of a 200-millisecond test pulse to −10mV. The pre-pulse voltage dependence was determined using a 100-millisecond prepulse to various potentials from a holding potential of −120mV, followed by a 20-millisecond test pulse to −10mV. Normalized conductance was plotted against voltage and fit with a Boltzmann function to determine the voltage at half-maximal inactivation ($V_{1/2}$ of inactivation) and slope factor $k$. Kinetics of recovery from channel inactivation was determined using a 1-second prepulse to −10mV from a holding potential of −120mV followed by a variable time delay to a 10-millisecond test pulse to −10mV. Data were fit with a double exponential function to determine the first ($\tau_1$) and second ($\tau_2$) time constants of recovery and their relative weights.

Ramp currents were obtained using a voltage ramp from −120 to +40mV at 0.8mV/ms. Peak current and total charge (area under the curve; in Coulombs) were calculated.

Pharmacologic experiments were performed via bath perfusion. 5,5-Diphenyldihydantoin (phenytoin) was from Sigma-Aldrich. Lacosamide (L098500) was purchased from Toronto Research Chemicals (Toronto, Ontario, Canada), dissolved in methanol, and stored as 100mM stock solution prior to 1:1,000 dilution in extracellular solution. For such experiments, control extracellular solution contained the same final concentration of methanol (0.0998%).

All recordings and data analysis were performed blind to experimental group.

**Data Analysis**

Data for standard electrophysiological parameters were obtained from at least n = 12 cells (1 from each coverslip) from at least 6 separate transfections for each experiment. Data were analyzed using Clampfit 10.6 (Molecular Devices) or using custom scripts written in MATLAB (MathWorks, Natick, MA), and statistics were generated and plotted using Statistical Package for the Social Sciences version 14 (SPSS, Chicago, IL), Microsoft Excel (Microsoft, Redmond, WA), Prism (GraphPad Software, La Jolla, CA), and Sigma Plot 11 (Systat Software, San Jose, CA). Results are presented as the mean ± standard error of the mean, and statistical significance was established using the p value calculated from a paired or unpaired Student t test, or via 1-way analysis of variance (ANOVA) with Bonferroni correction for multiple comparisons, as appropriate, with the p value specified at the p < 0.05, 0.01, or 0.001 level, or reported exactly.

**Results**

We identified a cohort of 4 patients with severe infantile onset epileptic encephalopathy and de novo heterozygous variants in SCN3A encoding the type 3 voltage-gated Na$^+$ channel α subunit Nav1.3 (Fig 1, Table 1). Two of the patients (Patients 1 and 2) carried the same de novo p.Ile875Thr variant, whereas the other 2 patients harbored unique de novo variants p.Pro1333Leu and p.Val1769Ala. We also included 2 patients with SCN3A variants that were presumed (Patient 5) or demonstrated to be inherited (Patient 6). The 4 patients (Patients 1–4) with confirmed de novo mutation had intractable epilepsy with onset during infancy and severe to profound developmental delay. MRI of the brain was essentially normal in all cases except for the 2 patients with
FIGURE 1: Locations of epilepsy-associated Nav1.3 variants. (A) Shown is a schematic of the Nav1.3 voltage-gated Na⁺ channel α subunit, with domains (D) 1 to 4, and transmembrane segments (S) 1 to 6 (shown for D1). Epilepsy-associated variants previously reported in the literature are shown as closed squares, and those described in the present report are shown as open circles. Variants in bold are recurrent. Amino acid location is based on Reference Sequence NP_008853.3 (hNav1.3 isoform 1). (B) Nav1.3 mutations associated with epileptic encephalopathy occur at highly conserved amino acid residues, as shown using ClustalX multiple sequence alignment of human Nav1.3 isoforms 1, 2, and 3, human Nav1.1 homolog, and various species orthologs. The Nav1.3 variants described in this report are indicated in bold above the corresponding amino acid residue. The highly conserved arginine residues of the S4 helix of the voltage sensor of Nav1.3 are indicated by the boxed regions. Notation indicates conservation across human Na⁺ channel genes and between species: colon, strongly similar; asterisk, fully conserved.
p.Ile875Thr mutation (Patients 1 and 2; Fig 2). Previously reported cases of Nav1.3 variants associated with epilepsy are summarized for comparison (Table 2).

Na\(^+\) channels are formed by a single polypeptide composed of 4 repeated domains (D1–D4), with each domain comprising 6 transmembrane segments (S1–S6); S1–S4 represent the voltage-sensing region, whereas S5–S6 forms the conducting pore. Identified variants in Patients 1–5 were in the S4–S6 domains (Tables 1 and 3). Figure 1B shows the sequence alignment between isoform 1 and isoforms 2 and 3 of hNav1.3 (see Subjects and Methods), between other human voltage-gated Na\(^+\) channel \(\alpha\) subunits, and across phylogeny. p.Ile875Thr identified in Patients 1 and 2 produces substitution of a hydrophobic isoleucine to polar uncharged threonine at a highly evolutionarily conserved residue located in the S4–S5 linker of D2. The p.Pro1333Leu mutation found in Patient 3 represents the substitution of a small, aliphatic amino acid proline by hydrophobic leucine at a residue located in the S4–S5 linker of D3 that is highly conserved between human Na\(^+\) channels Nav1.1–1.9 as well as across phylogeny. The p.Val1769Ala mutation in Patient 4 results in substitution of an alanine for valine at a highly conserved residue in the S6 segment of D4. The p.Arg1642Cys variant of unknown inheritance detected in the more mildly affected Patient 5 produces a substitution of a positively charged arginine for cysteine at a conserved residue in the S4–S5 linker of D4.

Reference to in silico prediction software PolyPhen-2 and SIFT supports the pathogenic nature of the variants identified in the patients in the cohort with early infantile epileptic encephalopathy (Table 4). Variants were absent from control databases including the genome Aggregation Database and the Exome Variant Server. We also queried ClinVar for mutations in the other epilepsy-associated sodium channel genes SCN1A, 2A, and 8A that were homologous to the SCN3A mutations reported here (Table 5) and determined that, for example, Nav1.1-p.Val1784Ala (an identical substitution at the position homologous to amino acid 1769 in Nav1.3) has...
been reported in a patient with severe myoclonic epilepsy of infancy (SMEI; Dravet syndrome). A recent report of 9 patients with an early profound form of SMEI reported 1 patient with a Nav1.1-p.Pro1345Ser mutation, an identical substitution at the amino acid residue homologous to position 1333 in SCN3A that is mutated in Patient 3 in our cohort. It should be noted that prior work has shown that homologous mutations in SCN1A and 3A can have divergent effects on channel physiology. Search of the online SCN1A database (http://www.molgen.ua.ac.be/SCN1AMutations/Home) revealed an additional case of a patient with genetic epilepsy with febrile seizures plus (GEFS+) due to familial p.Arg1657Cys missense mutation, an identical amino acid substitution at the position homologous to residue 1642 in Nav1.3 that was identified in Patient 5.

To assess the functional effects of these variants, we performed whole cell voltage-clamp electrophysiological recordings of wild-type hNav1.3 and mutant hNav1.3 expressed in tsA-201 cells coexpressed with wild-type human β1 and β2 auxiliary subunits. Representative rapidly activating and rapidly inactivating inward currents are shown (Fig 3A), with plots of average current density versus voltage (see Fig 3B, Table 4). Peak current density was 374.1 ± 18.5 pA/pF for wild type (n = 27); 391.1 ± 28.6 pA/pF for p.Ile875Thr (n = 14), and 411.5 ± 55.5 pA/pF for p.Pro1333Leu (n = 10), which was not different between groups (p = 0.27 and 0.20 for wild type vs p.Ile875Thr and p.Pro1333Leu, respectively). Rise time was also not statistically different between groups; time to peak current (in milliseconds) at −10 mV was 0.82 ± 0.05 for wild type (n = 27).

<table>
<thead>
<tr>
<th>TABLE 3. Biophysical Properties of WT Nav1.3 Channels and Nav1.3 Variants</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Current Density at −10mV</strong></td>
</tr>
<tr>
<td>pA/pF</td>
</tr>
<tr>
<td>WT</td>
</tr>
<tr>
<td>p.Ile875Thr</td>
</tr>
<tr>
<td>p.Pro1333Leu</td>
</tr>
<tr>
<td>p.Val1769Ala</td>
</tr>
<tr>
<td>p.Arg1642Cys</td>
</tr>
<tr>
<td>p.V1799Q</td>
</tr>
</tbody>
</table>

| p < 0.001 versus WT (1-way analysis of variance with Bonferroni correction for multiple comparisons). |
| p < 0.05 versus WT. |
| p < 0.01 versus WT. |

| TABLE 4. ClinVara Entries for Homologous Variants in Other Epilepsy-Associated Sodium Channel Genes |
|-------------------|-------------------|-------------------|-------------------|-------------------|
| **SCN1A** | **SCN2A** | **SCN8A** |
| p.Ile875Thr | 871 | N | NA | 873 | N | NA | 867 | N | NA |
| p.Pro1333Leu | 1345 | P1345S | SMEI | 1335 | N | NA | 1325 | N | NA |
| p.Val1769Ala | 1784 | V1784A | SMEI | 1774 | N | NA | 1764 | N | NA |
| p.Arg1642Cys | 1657 | N | NA | 1647 | R1647H | Nonspecific | 1638 | R1638H | Not provided |
| p.Lys1799Gln | 1814 | N | NA | 1804 | N | NA | 1794 | N | NA |

| a.a. = homologous amino acid residue; N = no; NA = not applicable; SMEI = severe myoclonic epilepsy of infancy (Dravet syndrome). |
Slightly higher peak current density values for p.Ile875Thr and p.Pro1333Leu are likely a consequence of a hyperpolarizing leftward shift in the voltage dependence of activation (see Fig 3B, C). In these 2 mutant channels, the voltage at which maximal inward current was observed was shifted in the hyperpolarized direction, being −15.9 ± 1.6 mV for wild-type hNav1.3 (n = 27), −28.9 ± 2.4 mV for p.Ile875Thr (n = 14, p < 0.01 vs wild type via 1-way ANOVA with Bonferroni correction for multiple comparisons), and −26.0 ± 2.8 for p.Pro1333Leu (n = 10, p < 0.01 vs wild type). In contrast, we did not observe a change in the voltage dependence of activation for Nav1.3-p.Val1769Ala (−17.6 ± 1.6, n = 27, p = 0.079 vs wild type via 1-way ANOVA).

We noted striking differences in the \(I_{\text{NaP}}\) between groups, defined here as residual noninactivating current at 200 milliseconds following a voltage step from −120 mV (see Fig 3D–F). \(I_{\text{NaP}}\) was 2.6 ± 0.4% (n = 27) of \(I_{\text{NaT}}\) for wild-type channels, but was 17.9 ± 3.4% for p.Ile875Thr (n = 12, p < 0.001 vs wild type), 10.7 ± 1.6% for p.Pro1333Leu (n = 14, p < 0.0001 vs wild type), and 30.7 ± 2.8% for p.Val1769Ala (n = 25, p < 0.0001 vs wild type). We noted that this current was not persistent per se,30–32 but rather inactivated with slow kinetics over the course of seconds for both wild-type and mutant Nav1.3 channels; for example, remaining current at 1 second following a voltage step to −10 mV was 0.7 ± 0.2% of peak \(I_{\text{NaT}}\) for wild-type Nav1.3 channels (n = 7), and 4.3 ± 1.4% (n = 7) of peak for Nav1.3-p.Val1769Ala. We also found that Nav1.3-p.Val1769Ala mutant channels displayed markedly larger currents (wild type, 197.1 ± 26.0 pA, n = 7; p.Val1769Ala, 1370.0 ± 305.0 pA, n = 12; p = 0.013) and larger total charge (wild type, 0.96 ± 0.13 nanocoulomb [nC], n = 7; p.Val1769Ala, 9.0 ± 2.0 nC, n = 12; p = 0.012) in response to 0.8 mV/ms slow depolarizations (Fig 4C).

Targeting persistent current is a proposed therapeutic strategy in epilepsy.33,34 As Nav1.3 mutants p.Ile875Thr, p.Pro1333Leu, and p.Val1769Ala showed increased persistent current relative to wild-type Nav1.3, we hypothesized that pharmacological agents that target \(I_{\text{NaP}}\) might normalize pathological epilepsy-associated Na\(^+\) channel current, and could represent potential treatments for SCN3A encephalopathy. We tested agents known to exert activity on this current component. The \(I_{\text{NaP}}\) component of Nav1.3 has been shown to be blocked by various antiseizure medications including phenytoin, lacosamide, topiramate, and carbamazepine.20,35 We first tested lacosamide, shown previously to act as a channel blocker primarily of Nav1.7,35–37 but also of Nav1.3 and Nav1.8.35
Consistent with previous results from wild-type Nav1.3,35 we found that 100 \( \mu \text{M} \) lacosamide had no effect on peak transient \( \text{Na}^+ \) current (before, 435.2 \( \pm \) 24.4 pA/pF; after, 447.4 \( \pm \) 21.2 pA/pF; \( n = 10, p = 0.41 \)). We did find that lacosamide produced a small but statistically significant block of persistent current, as...
measured at 200 milliseconds during a depolarizing pulse from $-120$ to $-10$mV (from $2.2 \pm 1.0\%$ to $0.8 \pm 0.2\%$ or $52.5 \pm 6.9\%$ block; $n = 10$, $p = 0.019$ via paired 2-tailed $t$ test). This effect did not wash out; however, the effect was seen after an incubation time of as little as 1 minute. We confirmed that this purported block by lacosamide was not due to rundown of $I_{NaP}$, as persistent current was stable for at least 15 minutes in control experiments performed without addition of lacosamide to the extracellular solution.

We then tested lacosamide on heterologously expressed Nav1.3 mutants and found that it produced a similar proportional decrease in $I_{NaP}$. In Nav1.3-p.Val1769Ala mutants, which exhibit the largest persistent current, $100\mu\text{M}$ lacosamide produced a $48.1 \pm 5.1\%$ block in $I_{NaP}$, from $33.0 \pm 4.1\%$ to $17.7 \pm 2.8\%$ of peak transient current ($n = 10$, $p < 0.001$). Similar effects ($63.7 \pm 1.2\%$ block and $49.9 \pm 6.7\%$ block) were seen in p.Ile875Thr and p.Pro1333Leu mutants (see Fig 4A, B).

We next tested phenytoin, also known to block persistent sodium current.\textsuperscript{30,38} In rat neocortical pyramidal neurons, phenytoin produces a hyperpolarizing shift in the voltage dependence of $I_{NaP}$ inactivation.\textsuperscript{30} One hundred micromolar phenytoin had a small effect on peak currents ($\text{control}, 3,002.6 \pm 244.0\text{pA}$; $n = 5$, $p = 0.9\%$ of peak transient current, a $34.7\%$ block) were seen in p.Ile875Thr and p.Pro1333Leu mutants (see Fig 4A, B). Phenytoin also reduced peak currents ($\text{control}, 19.8 \pm 0.7\text{pA/pF}$; $n = 5$, $p = 0.026$) and total charge ($\text{control}, 19.8 \pm 4.7\text{nC}$; phenytoin, $8.4 \pm 2.0\text{nC}$; $n = 5$, $p = 0.029$) in response to $0.8\text{mV/ps}$ slow ramp depolarizations from $-120\text{mV}$ (see Fig 4C, D).

**Discussion**

Here we demonstrate that heterozygous missense mutations in the gene $SCN3A$ encoding the voltage-gated $\text{Na}^+$ channel $\alpha$ subunit Nav1.3 are a cause of early infantile epileptic encephalopathy, identifying 3 causative variants in 4 patients. This conclusion is rigorously supported by multiple lines of evidence; the mutations are de novo and are absent from various control databases; the mutations occur at residues that exhibit a high level of evolutionary conservation; and functional studies demonstrate marked channel dysfunction. Mutations in other sodium channel genes $SCN1A$, 2A, and 8A, encoding Nav1.1, 1.2, and 1.6, respectively, have been previously determined to be important causes of severe epilepsy with onset in early childhood. With this report, the 4 major neurally expressed $\text{Na}^+$ channel genes have all been implicated as causes of early infantile epileptic encephalopathy.

By identifying patients with $SCN3A$-related early infantile epileptic encephalopathy ($SCN3A$ encephalopathy), we extend prior reports that have linked $SCN3A$ variants with milder forms of epilepsy. Holland et al reported a developmentally normal child with mild partial epilepsy onset at age 2 years with a heterozygous p.Lys354Gln $\text{Gln}$ variant in Nav1.3, which was inherited from the patient’s unaffected father.\textsuperscript{23} Estacion et al characterized rat $\text{Scn3a}$ harboring the corresponding variant p.Lys343Gln (r$\text{Scn3a}^\text{K343Q}$) in heterologous systems and found increased persistent current (from $4.4 \pm 0.4\%$ to $8.1 \pm 1.4\%$ of $I_{NaT}$).\textsuperscript{21} Vanoye et al performed specific targeted sequencing of $SCN3A$ in a cohort of epilepsy patients and reported 4 Nav1.3 variants associated with childhood onset epilepsy,\textsuperscript{22} although none of the patients had early onset epileptic encephalopathy and inheritance pattern was not available. One variant, p.Glu1160Lys...
(p.Glu1111Lys in hNav1.3 isoform 2), showed increased persistent current (1.2 ± 0.2% for p.Glu1111Lys versus 0.5 ± 0.1% for wild type). Lamar et al reported a patient with a de novo p.Leu247Pro mutation in Nav1.3 with developmental delay and focal epilepsy onset at 18 months\textsuperscript{24}; functional studies showed decreased current density as well as cell surface expression suggesting loss of function. Trujillano et al reported a single patient with

![Antiseizure medications partially normalize pathological persistent current in Nav1.3 mutant channels.](image)

**FIGURE 4**: Antiseizure medications partially normalize pathological persistent current in Nav1.3 mutant channels. (A) Traces showing peak transient sodium current and slowly inactivating/persistent current component ($I_{NaP}$) of wild-type (WT) and mutant Nav1.3 channels before (black traces) and after (gray traces) application of 100 μM lacosamide (LCM; A1) and phenytoin (PHE; A2). (B) Bar graph showing percentage blockade of $I_{NaP}$ by LCM (WT, n = 10; p.Ile875Thr, n = 6; p.Pro1333Leu, n = 6; p.Val1769Ala, n = 10) and PHE (WT, n = 3; p.Val1769Ala, n = 7). (C) Representative examples of Nav1.3 currents evoked by a voltage ramp from -120 to +40 mV at 0.8 mV/ms in WT Nav1.3 (top left) and p.Val1769Ala mutant channels (top right), with block by PHE (bottom). (D) Quantification of charge (in nanocoulombs [nC]) between WT Nav1.3 (n = 5) and p.Val1769Ala (n = 5) before and after drug application. All data are presented as mean ± standard error of the mean. *$p < 0.05$, **$p < 0.01$ via paired 2-tailed t test.
febrile seizures and epilepsy with a de novo SCN3A p.Pro1333Leu mutation, which is the same mutation seen in Patient 3 in our study, although additional details regarding the patient phenotype were not provided.39

Taken together, the results of our study combined with previous investigations suggest a spectrum of SCN3A-related phenotypes, ranging from mild epilepsy with normal neurocognitive development to early infantile epileptic encephalopathy. Our study suggests that SCN3A mutations causative of epileptic encephalopathy exhibit prominent gain of function with markedly increased noninactivating Na\(^+\) current, whereas variants identified in patients with milder phenotypes may result in loss of function or more subtle gain of function. For many of the previously reported cases of epilepsy associated with variants in SCN3A, inheritance could not be demonstrated, and such variants may represent rare population variants that could act as modifiers of disease or risk alleles rather than being causative of highly penetrant monogenic epilepsy per se.

Patients 1 and 2 in this study exhibited abnormal MRI showing polymicrogyria (see Fig 2). This was not a consistent feature of the cohort of patients with SCN3A encephalopathy, but was instead only seen in the two patients, who were unrelated, with the recurrent p.Ile875Thr variant, suggesting a potential mutation-specific effect on structural brain development. The basis of any association between SCN3A mutation and malformation of cerebral cortical development is unclear. Such an association could reflect a noncanonical ion channel function of Nav1.3, such as in mediating cell–cell interactions during cerebral cortical development, perhaps via interaction (or abnormal interaction) with or by auxiliary \(\beta\) subunits, which are known to have roles in cell adhesion. Alternatively, this could be due to an early deleterious effect of abnormal electrogensis on neuronal migration and cerebral cortical development. It should be noted that we cannot absolutely rule out the unlikely possibility of a contribution of a second, perhaps somatic, mutation, or mutation in an unknown gene, or of an early life insult such as infection or hypoxic ischemic brain injury, as contributory. Ascertainment of additional cases will be required to begin to clarify the issue of genotype:phenotype correlation and potential role of Nav1.3 in structural brain development. Of note, developmental brain malformations have also been found in patients with epilepsy with identified causative de novo mutations in other ion channels.40

Our findings offer the suggestion that SCN3A encephalopathy with onset in the first 2 months of life can be clearly differentiated from Dravet syndrome, which is mainly due to heterozygous loss of function of SCN1A.5,6 This presumably reflects the differential developmental expression pattern of these two genes, with SCN3A being expressed at high levels during embryogenesis and during early postnatal life, falling to nearly undetectable levels by adulthood in rodent brain (although low-level expression persists in adult brain tissue.13). In contrast, SCN1A expression is at low levels at birth, increasing in infancy and young childhood.12

The p.Ile875Thr and p.Pro1333Leu de novo mutations produce a marked leftward shift in the voltage dependence of activation of approximately 10mV. This finding is consistent with the location of these mutations in the S4–S5 linker, close to the positively charged arginine residues of the S4 helix domain of the voltage sensor. In addition, these mutations are located in D2 and 3, respectively: the first 3 domains are thought to be responsible for fast activation, which may account for the leftward shift in the voltage dependence of activation observed for these variants. The mutation identified in Patient 4 (p.Val1769Ala), which was not associated with a hyperpolarizing shift in the \(G-V\) curve (albeit smaller in magnitude), is located in D4.43,44 Although the exact mechanism of voltage-dependent activation of Na\(^+\) channels is not fully determined, it is thought that the S4–S5 linker translates voltage-dependent shifts of the S4 segment into opening of the pore,45 with motion of S4–S5 coupled to that of neighboring S5 and S6 segments.46

We also found increased slowly inactivating/persistent current in p.Ile875Thr, p.Pro1333Leu, and p.Val1769Ala, corresponding to the 3 de novo mutations identified in the patients with early onset epileptic encephalopathy in this cohort. The persistent sodium current \(I_{NaP}\) remains a somewhat enigmatic feature of Na\(^+\) channels and continues to be a subject of intense investigation. \(I_{NaP}\) is thought to be important for various cellular functions including regulation of repetitive firing and boosting of synaptic inputs, and in the generation of subthreshold membrane potential oscillations.31,32,47,48 Nav1.3 is known to exhibit \(I_{NaP}\) in heterologous systems as well as in neurons under normal and pathological conditions.21,49,50 The value for persistent current recorded here for wild-type Nav1.3 (2.6%) is higher that reported by Vanoye et al,22 similar to that previously by Estacion et al,21 and lower than reported by Sun et al.20 This current may not be truly “persistent,” but rather exhibits slow inactivation on the order of seconds or tens of seconds,30,32,47,51–53 as we have also shown here. We further found that the antiseizure medications lacosamide and phenytoin selectively blocked \(I_{NaP}\) over \(I_{NaT}\) and that block was proportional to the amplitude of the persistent current.
Previous data indicate that mutations in various sodium channels across all 4 domains including intracellular loops could affect the amplitude of $I_{NaP}$.\(^{54}\) The finding that Nav1.3-p.Ile875Thr (located in D2) and p.Val1769Ala (located in D4) were associated with the largest increase in $I_{NaP}$ is consistent with a recent report using the tarantula toxin RTX-VII. This toxin increases Nav1.3-mediated $I_{NaP}$ via interaction with D2 and D4.\(^{55}\) Interestingly, focal application of RTX-VII to the surface of the cerebral cortex of adult rats induced seizures, consistent with a potentially ictogenic effect of increased Nav1.3 $I_{NaP}$ and supporting the pathogenic mechanism proposed here. Why the p.Pro1333Leu mutation, located in D3, also increased $I_{NaP}$, remains unclear. Although additional work is required to further elucidate the structural basis of Nav1.3-mediated $I_{NaP}$, our results may provide some additional insight into this phenomenon.

We noted that the $E-V$ relation of Na\(^+\) channels containing Nav1.3-p.Val1769Ala exhibited a somewhat flat appearance at depolarized potentials. The basis of this observation is unclear and would require additional investigation, and may be attributable to allosteric modification of voltage-dependent gating by the Nav1.3-p.Val1769Ala mutation.

The inheritance pattern of the p.Arg1642Cys variant could not be definitively established. We did note that the p.Arg1642Cys variant is homologous to an p.Arg1657Cys missense mutation described in a family with GEFS+, and this difference between Dravet syndrome and the more mild GEFS parallels the difference in disease severity between Patient 5 and the more severe Patients 1–4 with proven de novo mutations. We did find that Nav1.3-p.Arg1642Cys channels appeared to recover from inactivation more rapidly, which might be predicted to increase neuronal excitability by supporting the ability to discharge action potentials repetitively. Further work will be required to better delineate the relationship of this variant to epilepsy and the mechanism whereby faster recovery from Na\(^+\) inactivation might produce cellular hyperexcitability.

The establishment of a gene-specific diagnosis is important, as it may have current or future treatment implications. For example, clinical data indicate that epilepsy in patients with Dravet syndrome responds best to specific antiseizure medications, whereas antiseizure medications with a predominant mechanism of action of Na\(^+\) channel blockade may exacerbate seizures and are considered to be contraindicated.\(^{56,57}\) In contrast, recent reports suggest that epilepsy in some patients with SCN8A encephalopathy may respond well to sodium channel antagonists such as phenytoin.\(^{7,58}\) Our data raise the possibility that early introduction of agents specifically targeting Nav1.3-mediated persistent Na\(^+\) current, during the transient developmental time period within which this channel is expressed, represents a potential strategy for treatment of SCN3A encephalopathy.

In conclusion, we report a cohort of 4 patients with infantile onset epileptic encephalopathy due to de novo heterozygous gain-of-function missense mutations in the gene SCN3A encoding the type 3 voltage-gated sodium channel Nav1.3. Mutant channels exhibited various mechanisms of gain of function, including activation at hyperpolarized potentials, and enhanced persistent current. We hypothesize that SCN3A encephalopathy presents in the early infantile period due to the developmental expression pattern of SCN3A, combined with prominent gain-of-function effects predicted to increase neuronal excitability. We further show that the enhanced persistent current seen in mutant channels may be selectively inhibited with the antiseizure medications lacosamide and phenytoin. Given the transient developmental trajectory of SCN3A, it is hoped that partial normalization of pathological epilepsy-associated ion channel activity in the neonatal period in patients with SCN3A encephalopathy could protect the newborn brain until Nav1.3 is replaced by Nav1.1, 1.2, and 1.6, later in infancy.

Acknowledgment

This work was supported by NIH National Institute of Neurological Disorders and Stroke (K08 NS097633) and the Burroughs Wellcome Fund Career Award for Medical Scientists to E.M.G.

We thank T. Hoshi, D. Ren, and E. D. Marsh for discussions and a critical reading of the manuscript; M. Covarrubias for a tsA-201 cell line; L. L. Isom for the gift of a β-1 cDNA clone; and A. L. George for the gift of a β-2 cDNA clone.

Author Contributions

T.Z., I.H., and E.M.G., contributed to the conception and design of the study; all authors contributed to the acquisition and analysis of data; T.Z. and E.M.G. contributed to drafting the text and preparing the figures.

Potential Conflicts of Interest

Nothing to report.

References


